logo-loader
NASDAQ:ADAP

Adaptimmune Therapeutics

Receive alerts
Market:
NASDAQ
Price
1.47 USD
Day Change
-0.68%
Market Cap:
$362.83 m
52 weeks high
2.05
52 weeks low
0.42

In brief

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.